A wide economic moat, free cash flow that converts at 185% of net income, four consecutive earnings beats, and a strong technical breakout establish high underlying quality — but the stock has already moved above the near-term resistance target, and at the current price the reward-to-risk ratio is negative, leaving no attractive entry point for new capital.
Thesis pillars
- Wide Moat Superior Cash Conversion→Stable
- Consistent Earnings Execution→Stable
- Strong Price Momentum Breakout→Stable
- +1 more pillar — see the Why tab for full reasoning
LivaNova PLC (LIVN) Stock Analysis
Breakout setup
Healthcare · Medical Devices
Hold if already holding. Not a fresh buy at $83.62, but acceptable to hold if already in. Reasons: Analyst target reached - limited upside remaining; Near 52-week high (0.4% away).
LivaNova PLC designs and sells medical devices across two segments — Cardiopulmonary (heart-lung machines, oxygenators, and perfusion systems) and Neuromodulation (VNS Therapy System for drug-resistant epilepsy and treatment-resistant depression). The U.S., Europe, and Rest of... Read more
Hold if already holding. Not a fresh buy at $83.62, but acceptable to hold if already in. Reasons: Analyst target reached - limited upside remaining; Near 52-week high (0.4% away). Chart setup: Golden cross, above all MAs, RSI 69, MACD bullish. Maintain position. Not compelling to add more. Score 5.7/10, moderate confidence.
Passes 8/10 gates (positive momentum, clean insider activity, no SEC red flags, news boost analyst 0.35, news boost analyst cluster(5), earnings proximity 33d clear, semi cycle peak clear, materials cycle peak clear). Fails on favorable risk/reward ratio. Suitability: aggressive.
About LivaNova PLC
About LivaNova PLC
LivaNova PLC reported net revenue split as 53% from the United States, 19% from Europe, and 28% from the rest of world for the year ended December 31, 2025, across two reportable segments — Cardiopulmonary and Neuromodulation. Cardiopulmonary products include heart-lung machines (HLMs), oxygenators, autotransfusion systems, perfusion tubing, and cannulae, while Neuromodulation centers on the VNS Therapy System for drug-resistant epilepsy and treatment-resistant depression, approved in many jurisdictions globally including the United States for patients four years of age or older.
LivaNova earns device sales revenue from hospitals, perfusionists, neurologists, neurosurgeons, and other healthcare professionals in more than 100 countries through direct sales representatives, agents, and independent distributors. In Cardiopulmonary, the flagship Essenz Perfusion System and Inspire oxygenator range (12 models) are capital equipment sold alongside disposable perfusion tubing, cannulae, and autotransfusion consumables that generate recurring procedure-driven revenue. In Neuromodulation, the VNS Therapy generator replacement cycle — batteries deplete over time and leads do not require removal to replace depleted generators — supports recurring procedure revenue. Primary medical device competitors include Terumo Medical Corporation, Maquet Medical Systems, Medtronic plc, Haemonetics Corporation, Spectrum Medical Limited, and NeuroPace, Inc., depending on product line. LivaNova manufactures at facilities in the United States, Italy, Germany, Australia, and Brazil, with certain components procured from single suppliers for quality assurance or cost reasons.
Show full overview
LivaNova's VNS Therapy System for treatment-resistant depression faces an unresolved Medicare coverage pathway. In 2007, CMS issued a national coverage determination that VNS is not covered for treatment-resistant depression. The 2019 CED arrangement permitted coverage only within a randomized controlled clinical study; the RECOVER trial completed enrollment of the unipolar cohort by 2023 but announced in 2024 that primary endpoints were not met, though statistically significant improvements appeared in multiple secondary endpoints. In June 2025, LivaNova initiated reconsideration proceedings with CMS to seek national Medicare coverage for unipolar treatment-resistant depression patients — a decision that remained pending at year-end and represents a material reimbursement binary for the Neuromodulation segment.
See also: Healthcare · Medical Devices
From LivaNova PLC's most recent 10-K filing, extracted June 11, 2026.
Recent developments
updated 2026-07-06Recent Developments — LivaNova PLC
Latest news
- NEWS LivaNova (LIVN) Projected to Post Earnings on Wednesday - MarketBeat — MarketBeat neutral
- NEWS LivaNova PLC (LIVN) Shares Fall 3.3% -- GF Value Says Still Over - GuruFocus — GuruFocus neutral
- NEWS Press Release: LivaNova to Announce Second-Quarter 2026 Results - Moomoo — Moomoo neutral
- NEWS [Form 4] LivaNova PLC Insider Trading Activity - Stock Titan — Stock Titan neutral
- NEWS LivaNova Reports Improved OSA Outcomes With PolySync Programming - TradingView — TradingView positive
Generated 2026-07-06T04:40:27Z.
Upcoming dated catalysts
Thesis
Key Metrics
Quality Signals
Options Flow
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Rating Breakdown
1 floor-breaker
Technicals below the gate floor. Component breakdown shows what dragged the score down.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Hold if already holding. Not a fresh buy at $83.62, but acceptable to hold if already in. Reasons: Analyst target reached - limited upside remaining; Near 52-week high (0.4% away). Chart setup: Golden cross, above all MAs, RSI 69, MACD bullish. Maintain position. Not compelling to add more. Target $82.30 (-1.6%), stop $79.34 (−5.4%), A.R:R -1.1:1. Score 5.7/10, moderate confidence.
Take-profit target: $82.30 (-1.6% upside). Target $82.30 (-1.6%), stop $79.34 (−5.4%), A.R:R -1.1:1. Stop-loss: $79.34.
Analyst target reached - limited upside remaining; Near 52-week high (0.4% away).
LivaNova PLC trades at a P/E of 42.7 (forward 18.1). TrendMatrix value score: 5.2/10. Verdict: Hold.
16 analysts cover LIVN with a consensus score of 4.2/5. Average price target: $81.
What does LivaNova PLC do?LivaNova PLC designs and sells medical devices across two segments — Cardiopulmonary (heart-lung machines, oxygenators,...
LivaNova PLC designs and sells medical devices across two segments — Cardiopulmonary (heart-lung machines, oxygenators, and perfusion systems) and Neuromodulation (VNS Therapy System for drug-resistant epilepsy and treatment-resistant depression). The U.S., Europe, and Rest of World accounted for 53%, 19%, and 28% of total net revenue for 2025, with distribution in more than 100 countries.